Analyzing the clinical benefit of newer therapies for advanced or metastatic non-small-cell lung cancer: application of the ESMO-magnitude of clinical benefit scale v1.1.
Ricardo García-FumeroCristina Fernández-LópezMiguel Ángel Ma Calleja-HernándezJosé Expósito-HernándezPublished in: Acta oncologica (Stockholm, Sweden) (2021)
Almost half of the RCTs showing a statistically significant result favoring the experimental arm, failed to demonstrate a substantial clinical benefit according to the ESMO framework.
Keyphrases